The T1/ST2 ELISA allows researchers to accurately quantitate protein levels in under 3 hours.
Saint Paul, MN (PRWEB) March 29, 2010
MD Bioproducts, a division of MD Biosciences, Inc announces the launch of its new Mouse T1/ST2 ELISA for the study of inflammatory conditions. The ELISA offers researchers a rapid and accurate method to measure mouse serum and cell culture supernate levels of T1/ST2. The assay measures samples in the range of 0.156 – 10 ng/mL with a sensitivity of 0.05 ng/mL. Results can be obtained in less than 3 hours. In addition to the T1/ST2 ELISA, MD Bioproducts also offers researchers T1/ST2 antibodies for other related research applications such as IHC, western blotting, and flow cytometry.
ST2, also know as IL-1 R4 and T1 is an interleukin-1 receptor family glycoprotein that contributes to Th2 immune responses. ST2 is expressed on the surface of mast cells, activated Th2 cells, macrophages and cardio myocytes. It binds IL-33, a cytokine that is up regulated by inflammation or mechanical strain in smooth muscle cells, keratinocytes, airway epithelia and cardiac fibroblasts. The soluble ST2 isoform is released by activated Th2 cells and strained cardiac myocytes and is elevated in the serum in allergic asthma. The roles of T1/ST2 and IL-33 have been investigated in many immune responses such as allergy, asthma, rheumatoid arthritis and osteoarthritis.
About MD Bioproducts
MD Bioproducts is a division of the privately-owned company MD Biosciences, Inc. offering products for use in the inflammations, neurology, endocrinology, and metabolic disorders research fields. Since beginning operations in the U.S., based out of St. Paul, Minnesota, MD Biosciences has experienced significant development and grown to a company of 60 employees.
About MD Biosciences
MD Biosciences provides pre-clinical contract research services for companies engaged in inflammations and neurology research. The company is headquartered in Switzerland under Morwell Diagnostics and has specialized laboratories located in Minnesota, Glasgow, and Israel. A panel of scientific experts provides companies’ in-depth expertise and technologies to tackle problems and provide flexible drug discovery solutions, enabling smarter results faster.
The information in this press release should be considered accurate only as of the date of the release. MD Biosciences has no intention of updating and specifically disclaims any duty to update the information in these press releases.